METABOLIC REPROGRAMMING AS A STRATEGY TO DISARM NEURO-INFLAMMATION IN ENDOMETRIOSIS: A PRECLINICAL ASSESSMENT OF PYRUVATE DEHYDROGENASE KINASE INHIBITION

The preclinical paper assesses whether inhibiting pyruvate dehydrogenase kinase can “disarm” neuro-inflammation in endometriosis by targeting metabolic reprogramming. Using an endometriosis-relevant experimental model, the authors report that PDH kinase inhibition modulates metabolic pathways associated with neuroinflammatory processes and reduces inflammatory activity in the studied neuroinflammatory context. A key caveat is that the work is preclinical and therefore limited to model-based evidence rather than demonstrating clinical effects in people. This paper is centrally about endometriosis — it evaluates PDH kinase inhibition as a metabolic strategy to reduce neuro-inflammation in endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works